ARJUNA Therapeutics 

We are develpoing a new class of small molecules to tackle untreatable cancer.

OWNER

Ross Breckenridge (See Profile)


Sector

Biotech

Stage

Prototyping, preclinical

Country

Spain


The first quantum chemical developed as a drug (and we have a platform of unique molecules with uncorrelated MOA).

Unique mechanism of action acting rapidly and selectively on cancer mitochondria.

Very large potential markets in untreatable cancers in Europe and Asia

Very favourable safety profile, allowing long-term dosing and combination with other treatments.

Rapid penetration across the blood brain barrier.

Status

Pending

IP Type

Patent

Time

Countries

Australia
Austria
Belgium
Canada
China
Denmark
Finland
France
Germany
Israel
Italy
Japan
Netherlands
Russia
South Korea
Spain
Switzerland
USA
United Kingdom

Coverage

Manufacturing, therapeutic use as single agent or in combination for cancer and some non-cancer indications.

This information is confidential, do not share or copy.

Under evaluation at least till: May 8th, 2022

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2022 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar